Lifecare ASA (LIFE-ME.OL), on Tuesday, said it has received approval from the Regional Committee for Medical and Health Research Ethics or REK in Norway for its upcoming first-in-human trial of its implantable CGM sensor.
This approval marks a pivotal milestone toward regulatory validation of Lifecare's wireless glucose sensor, designed for individuals with type 1 diabetes. The trial will evaluate the sensor's safety, tolerability, and glucose-sensing precision in a clinical setting.
While the ethics approval indicates strong foundational support, it remains conditional pending minor documentation updates. Lifecare is currently awaiting final trial authorization from the Norwegian Medicines Agency (Direktoratet for medisinske produkter).
The study will be conducted across clinical sites in Norway and Germany, in collaboration with academic and clinical partners. The ethics greenlight follows recent technical validations confirming the device's compliance with core RF and electromagnetic compatibility standards.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.